Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,803 total articles
Revolution Medicines (RVMD) surged after 04/13/2026 Phase 3 RASolute 302 results showed daraxonrasib doubled overall survival versus chemo in metastatic pancreatic cancer (13.2 vs. 6.7 months). With a market cap near $29.07B, strong balance-sheet metrics and a clear regulatory path, the stock has runway for further upside — but expect volatility. T…
CoreWeave is winning the AI GPU war with large multi-year deals and pricing power, but the company is consuming cash at scale and is richly valued. For traders, the near-term setup favors a tactical short: momentum has run, technicals are stretched, and a correction would reprice the balance between growth and cash reality.
Energy Transfer (ET) blends a 7%+ yield with fee-heavy, contract-backed cash flow and pipeline optionality. At roughly $18.70 and a market cap near $64B, the security trades at reasonable multiples (P/E ~15.5, EV/EBITDA ~8.8) while generating multi-billion dollar free cash flow. I view the risk-reward as favorable for patient income-focused investo…
Flutter Entertainment's recent sell-off prices in legitimate risks but exaggerates the company's downside. With a $18.7B market cap, steady free cash flow ($569M), and regulatory developments that favor licensed incumbents, the setup is favorable for a mid-term rebound. This trade proposes a directional long with a clear entry at $106.50, a stop at…
CoreWeave is an AI-focused GPU-cloud operator that has locked up multi-year, multibillion-dollar deals and raised prices amid persistent GPU scarcity. The company trades at growth multiples consistent with a winner-take-most infrastructure story; this trade targets shareholders who believe CoreWeave can convert backlog, defend pricing, and scale pr…
AppLovin (APP) has had a choppy run since its 52-week high, but the company still prints strong profitability metrics and AI-driven product catalysts. With a market cap near $147B and a P/E in the low 40s, the stock looks buyable for a swing trade given recent technical setup and fundamental upside from Axon. Entry at the current levels, a discipli…
The GPU capacity squeeze is real and showing up in rental prices and enterprise procurement cycles. Nvidia sits at the center of that bottleneck: high-margin data-center revenue, massive free cash flow and an effective pricing mechanism through OEM and cloud partners. This trade idea takes a tactical long on NVDA into the next 45 trading days, with…
Nvidia's business remains the primary beneficiary of the AI infrastructure boom: dominant GPUs, high margins, and huge free cash flow. The stock has pulled back on valuation compression despite continued revenue and cash generation. We upgrade to Buy and lay out an actionable trade plan: enter at $195.00, stop at $170.00, target $320.00 over a flex…
Ezcorp's recent deal-making has shifted the investment case from a pure turnaround to a cash-flowing rollup with clear operational optionality. The shares trade at reasonable multiples (EV/EBITDA ~9.8, P/B ~1.71) and the company just pushed to a new 52-week high after consolidating 105 stores into Founders and adding dozens more in Mexico. I rate E…
FTAI Aviation has shifted from a pure-play engine lessor/aftermarket operator into a hybrid aerospace-and-infrastructure growth story. The company pairs a deep feedstock pipeline for CFM56/V2500 engines with a nascent FTAI Power business that converts retired jet engines into data center turbines. At a market cap near $28.0B and with partners like …
Applied Optoelectronics is shipping sizable 800G and 1.6T transceiver orders and building large-scale capacity in Texas and Taiwan. The market is fixated on rich multiples but is underpricing near-term revenue and unit-volume cadence tied to these orders. This trade targets a capture of the capacity-led re-rating while keeping risk controlled with …
Hewlett Packard Enterprise is benefitting from accelerating AI inference and networking demand. Q1 beat and an EPS guide of $2.30-$2.50 make today’s $24s an attractive entry for a mid-term swing trade. Valuation (implied forward P/E ~10x) is reasonable vs. cash flow and leverage metrics; the trade is predicated on continued strength in networking a…
loanDepot (LDI) looks cheap on equity terms but expensive on enterprise metrics. With management changes, constructive technicals and potential tailwinds to mortgage volumes, a disciplined long trade with a tight stop captures asymmetric upside if the company shows continued cash-flow stabilization and lower losses.
Goldman Sachs faces visible headwinds in the near term - slower deal flow, rate-driven trading normalization, and margin pressure - but its franchise, capital position, and pivot to fee-rich businesses justify a longer-term constructive stance. This trade lays out a concrete entry, stop and target with time horizons and catalysts to watch.
Century Communities (CCS) is trading below its recent highs on cyclical weakness, but a healthy balance sheet, positive free cash flow and a conservative valuation make a compelling long trade. We lay out an entry at $61.00, a $76.00 target and a $54.00 stop. The trade favors a recovery over the next 46-180 trading days if housing demand stabilizes…
BHP is positioned to benefit from structural copper demand and diversified commodity cash flow. With a $200.3B market cap, a 3.4% yield and recent technical strength, we upgrade the rating and lay out an actionable long trade with defined entry, stop and target while acknowledging headline-driven volatility.
Circle (CRCL) has been punished for regulatory and margin fears, but the company still sits on solid free cash flow, a dominant position with USD Coin, and light balance-sheet leverage. This trade idea outlines a swing entry with strict risk controls and a clear view of catalysts that could re-rate the stock back toward analyst targets.
Oracle has re-entered investors' crosshairs after a two-session surge driven by AI platform news, a large $553B RPO backlog and a data-center sustainability tie-up. The shares now carry software-like multiples (P/E ~28, P/S ~7, PB >13) while the business still carries heavy infrastructure spend and negative free cash flow. This idea is a tactical l…
We recommend a tactical long on Bombardier, playing continued premium demand for business jets against macro uncertainty. Use a disciplined entry at $1.80, a stop at $1.40, and an initial target of $2.70 over a mid-term 45 trading-day horizon. The thesis rests on affluent buyer strength, limited new supply, and attractive asymmetric upside against …
Fortescue is uniquely positioned: a high-margin iron ore cash engine funding aggressive investment in green hydrogen and battery metals. For investors willing to tolerate execution and commodity risk, buy the pullbacks and treat the position as a long-term play on industrial decarbonization.
Accenture is a lower-risk way to play enterprise AI adoption and managed services. The stock has been punished despite healthy cash flow, a modest debt load, and ongoing AI investments. At roughly $117.6B market cap and a P/E near 15.5, the risk/reward favors a long position with a clear stop and a target that assumes a modest multiple re-rating al…
Blue Owl Capital's BDC (OBDC) is trading at steep discount-to-book and high yield, but mounting credit fears, outsized short activity, and recent liquidity maneuvers create a tactical short opportunity. Entry $11.30, target $9.40, stop $12.10. Mid-term trade (45 trading days).
Synopsys is a high-quality EDA and IP franchise trading at premium multiples but with measurable de-risking catalysts: the Ansys deal, growing demand for software-defined product workflows (electronics digital twin), and solid free cash flow. This trade idea lays out an actionable long trade with entry, stop, and target levels tied to a 120-trading…
Novo Nordisk sits at the center of an increasingly binary GLP-1 fight. Eli Lilly's recent drug approvals and a stronger clinical edge for some pipeline assets increase the odds of market-share losses; Novo's valuation looks reasonable on paper but may not price in near-term revenue pressure. This trade idea proposes a mid-term short to capture furt…
Joby Aviation has the cash runway, regulatory progress and commercial partners that justify a constructive trade idea. The stock remains volatile and richly valued versus tiny revenue today, so this is a risk-on, event-driven trade: buy on market pullbacks around $8.79, target $14 on re-rating and early commercial revenue, stop at $6.50 to limit ca…
